Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe immune cells in cystic fibrosis – no new drug, just knowledge

NCT ID NCT04970225

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at blood neutrophils (a type of immune cell) in 47 adults with cystic fibrosis. Researchers compared these cells between patients and healthy donors, and also examined how chronic infection, CFTR modulator drugs, and lung flare-ups affect neutrophil behavior. The goal was to better understand the disease, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

47 people

The number who actually took part.

Started

Jul 2021

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over the age of 18 who is not under legal protection * Patients with CF according to the diagnostic criteria of the Cystic Fibrosis Foundation including: * 15 patients with severe mutation but not chronically infected with PA and not treated with lumacaftor / ivacaftor * 15 patients homozygous phe508del, chronically infected with PA and not treated with lumacaftor / ivacaftor * 15 patients homozygous phe508del, chronically infected with PA and treated with lumacaftor / ivacaftor * 15 hospitalized patients for respiratory exacerbation * 40 patients initiating Ivacaftor-Tezacaftor-Elexacaftor treatment. * No change in baseline treatment for 15 days (including antibiotic treatment). * Patient affiliated to a social security system * Free, informed and written consent, dated and signed by the patient and the investigator, at the latest on the day of inclusion and before any action required by the study. Exclusion Criteria: * Informed consent impossible to obtain * Involvement in an interventional research protocol in the previous 3 months if exclusion directive was given in this protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cystic fibrosis Pseudomonas infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cystic fibrosis

Contacts and locations

Locations

  • Cochin hospital, AP-HP

    Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.